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abstract
PURPOSE A challenge in the diagnosis of renal cell carcinoma (RCC) is to distinguish chromophobe RCC
(chRCC) from benign renal oncocytoma, because these tumor types are histologically and morphologically
similar, yet they require different clinical management. Molecular biomarkers could provide a way of dis-
tinguishing oncocytoma from chRCC, which could prevent unnecessary treatment of oncocytoma. Such
biomarkers could also be applied to preoperative biopsy specimens such as needle core biopsy specimens, to
avoid unnecessary surgery of oncocytoma.
METHODS We profiled DNA methylation in fresh-frozen oncocytoma and chRCC tumors and adjacent normal
tissue and usedmachine learning to identify a signature of differentially methylated cytosine-phosphate-guanine
sites (CpGs) that robustly distinguish oncocytoma from chRCC.
RESULTSUnsupervised clustering of Stanford and preexisting RCC data from The Cancer Genome Atlas (TCGA)
revealed that of all RCC subtypes, oncocytoma is most similar to chRCC. Unexpectedly, however, oncocytoma
features more extensive, overall abnormal methylation than does chRCC. We identified 79 CpGs with large
methylation differences between oncocytoma and chRCC. A diagnostic model trained on 30 CpGs could
distinguish oncocytoma from chRCC in 10-fold cross-validation (area under the receiver operating curve [AUC],
0.96 (95%CI, 0.88 to 1.00)) and could distinguish TCGA chRCCs from an independent set of oncocytomas from
a previous study (AUC, 0.87). This signature also separated oncocytoma from other RCC subtypes and normal
tissue, revealing it as a standalone diagnostic biomarker for oncocytoma.
CONCLUSION This CpG signature could be developed as a clinical biomarker to support differential diagnosis of
oncocytoma and chRCC in surgical samples. With improved biopsy techniques, this signature could be applied
to preoperative biopsy specimens.
JCO Precis Oncol 4:1141-1151. © 2020 by American Society of Clinical Oncology
INTRODUCTION
Renal cell carcinoma (RCC) is the sixth most common
cancer diagnosis among men and eighth most com-
mon among women.1 Small RCCs are generally as-
sociated with good prognosis in the absence of
metastasis or local invasion. However, early-stage RCC
is usually asymptomatic; therefore, many RCCs are
detected at later stages, resulting in poorer prognosis.2
A prerequisite for developing a clinically applicable
diagnostic biomarker for RCC is to identify markers that
can distinguish RCC from noncancerous renal tumors
such as a renal oncocytoma, which is the most
common benign histology discovered at the time of
surgery.3 Failure to distinguish oncocytomas from RCC
can lead to overdiagnosis and overtreatment of
oncocytoma, in the form of unnecessary or excessive
surgery.3-5 Oncocytomas are benign tumors composed
of oncocytes (epithelial cells that contain excessive
mitochondria), which are partially recognized because
of their eosinophilic histology (ie, eosin dye staining on
hematoxylin-and-eosin–stained slides).3
A longstanding challenge in RCC biomarker devel-
opment is to distinguish oncocytoma from chromo-
phobe RCCs (chRCCs), which are cytological and
morphologically similar and are understood to share
a cell of origin (ie, distal nephron epithelial cells).6,7 It is
particularly challenging to distinguish oncocytoma
from the “eosinophilic” chRCC, a chRCC subtype that
shares hallmark morphologic and genetic features
with oncocytoma.8,9 In clinical care, it is challenging to
distinguish oncocytoma from chRCC using renal tumor
biopsy samples, and pathologists often require large
amounts of tissue for a definitive diagnosis (eg, the
surgically resected tumor). For this reason, patholo-
gists often cannot distinguish oncocytoma from chRCC
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Here, we investigate DNA methylation, an epigenetic
modification that is perturbed in virtually all cancers,11 as
a source of diagnostic biomarkers to distinguish between
oncocytoma and chRCC. We profiled genome-wide pat-
terns of DNA methylation in both oncocytoma and chRCC,
enabling us to characterize methylation differences be-
tween these two histologies. We identified DNAmethylation
signatures that can classify oncocytoma and chRCC with




Study approval was obtained from the Stanford Institutional
Review Board (protocol no. 26213). Primary tumor tissue
samples were collected from patients with RCC or onco-
cytoma who were treated at Stanford Hospital. Samples
were collected at the time of extirpative surgery and freshly
frozen. Details of patient clinicopathologic features are
provided in the Data Supplement and are summarized in
Table 1.
DNA Methylation Arrays
DNA methylation profiles were generated from the Stanford
study patients’ samples using the Illumina Infinium
HumanMethylation450 Beadchip array (ie, the “450k ar-
ray”), as described in the Data Supplement.
Identification of Differentially Methylated CpGs
Significance of microarrays (SAM)12 analysis was used to
identify CpGs that were differentially methylated between
sample types, as described in the Data Supplement.
Development of Sample Group Diagnostic Classifiers
Using Modeling on DNA Methylation
Prediction of microarrays (PAM) analysis13 was used to
develop diagnostic models to classify or distinguish be-
tween sample types (renal mass types and tumor-adjacent
normal kidney parenchyma [NKP]), as described in the
Data Supplement.
Development of a Diagnostic Model Trained on Data From
The Cancer Genome Atlas to Classify Stanford
Study Samples
PAM analysis13 was used to train a model to classify clear-
cell RCC (ccRCC), papillary RCC (pRCC), chRCC, and NKP
using The Cancer Genome Atlas (TCGA) RCC study data.
This model was then applied to classify Stanford study
samples as one of the training sample classes. PAM
analysis was trained on DNAmethylation data for CpGs that
were abnormally methylated in RCC relative to NKP
(identified using MethylMix14).
Inferring Tumor Purity
We applied InfiniumPurify15 to calculate tumor purity
scores for surgical samples and biopsy specimens, as
described in the Data Supplement.
Validation of the Diagnostic Model in Independent
Patient Samples
PAM analysis was used to train a model on TCGA chRCC,
oncocytoma, and NKP DNA methylation data and then
classify oncocytoma and chRCC tumors from a “test set” of
tumor samples derived from previously reported in-
dependent studies.16,17 Test-set data included DNA
methylation Illumina 450k array data for formalin-fixed,
paraffin-embedded oncocytoma tumors (n = 37) from
a study by Chopra et al,16 and of fresh-frozen chRCC tumors
(n = 65) from the TCGA study.18 The Data Supplement
provides a description of the Chopra et al study data.
Classification of Ex Vivo Core Needle Biopsy Specimens
A 3-class PAM diagnostic model was applied to DNA
methylation profiles of ex vivo core needle biopsy speci-
mens that were collected from tumors and NKP of chRCC
and oncocytoma as part of the Chopra et al study.16
RESULTS
DNA Methylation-Based Classification of Oncocytoma
We first sought to classify oncocytoma in terms of its similarity
tomalignant RCC histological subtypes at the level of abnormal
CONTEXT
Key Objective
We profiled DNA methylation to determine if it is possible to distinguish oncocytoma from chromophobe renal cell carcinoma
(chRCC).
Knowledge Generated
We found that oncocytoma has a similar DNAmethylation profile to chRCC but features more extensive abnormal methylation;
this suggests that oncocytoma does not represent a precursor lesion that can progress to chRCC, as was previously
conjectured. We identified a methylation signature that could reproducibly distinguish oncocytoma from chRCC with high
accuracy and also distinguishes oncocytoma from other RCC subtypes.
Relevance
This signature could be applied as a diagnostic biomarker to distinguish oncocytoma from RCC in surgical samples to prevent
overdiagnosis and overtreatment of oncocytoma.
Brennan et al
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DNAmethylation. To do this, we appliedMethylMix14 to identify
abnormally methylated CpGs in RCC (Data Supplement). We
then applied PAM analysis to methylation data for all abnor-
mally methylated CpGs to develop a DNA methylation-based
diagnostic model that could classify RCC subtypes.13 We
trained this PAMmodel to classify chRCC (n = 65), ccRCC (n =
315), pRCC (n = 275), and NKP (n = 204), using TGCA DNA
methylation data sets. Ten-fold cross-validation was used to
test the performance of this model, indicating that it classified
NKP with perfect accuracy, and pRCC, ccRCC, and chRCC
tumors with 90%-92% accuracy (overall multiple-class area
under the curve [AUC], 0.97; Data Supplement).
We then used this model to classify tumor and NKP
samples that were collected from patients diagnosed with
oncocytoma and chRCC at Stanford (Table 1). All the
chRCC, NKP, and ccRCC samples were correctly classified,
validating the diagnostic model using samples from an
external data set (Data Supplement). Using this un-
supervised external model, 11 of 12 oncocytomas were
classified as most similar to chRCC; the remaining onco-
cytoma tumor was most similar to NKP. The similarity of
oncocytomas to chRCC at the level of methylation was
particularly apparent when the relative distances of each
patient sample were visualized (Fig 1).
TABLE 1. Demographics and Clinical Characteristics of Patient Samples
Tumor Type and Identification No.
Collection




1 Surgical pT2aNX 10 M 77 White Yes
3 Surgical pT2b 10 F 44 White Yes
4 Surgical pT2aNX 8.5 F 51 Hispanic Yes
9 Surgical pT1bN0 5 F 42 Hispanic Yes
10 Surgical pT3aNX 14 F 67 Hispanic Yes
2 Surgical pT1b 4.1 M 69 White No
7 Surgical pT2aNXMX 8 M 78 White No
17 Surgical pT1aNX 3.2 M 74 White No
Oncocytoma
5 Surgical N/A 5.3 M 69 White Yes
8 Surgical N/A 9.6 F 67 White Yes
11 Surgical N/A 11.5 M 74 Black Yes
12 Surgical N/A 10 M 78 White Yes
18 Surgical N/A 6 M 68 White Yes
19 Surgical N/A 8.6 M 79 Hispanic Yes
14 Surgical N/A 2.4 M 34 Unknown Yes
15 Surgical N/A 2.2 M 62 White No
20 Surgical N/A 5.8 M 82 White No
21 Surgical N/A 3.6 M 68 White No
22 FNA N/A 7 F 75 White No
23 FNA N/A 13 M 57 White No
Renal neoplasm of unclear pathologic
diagnosis
Hybrid_onc_chRCC_type_6 Surgical N/A 6 M 57 Black Yes
Hybrid_onc_chRCC_type_13 Surgical pT1a 2.8 M 73 White No
Hybrid_onc_RN_16 Surgical pT1a 2 M 57 White Yes
ccRCC
24 FNA pT3cN0 9 M 71 White Yes
25 FNA pT1bNX 7 F 64 Hispanic No
Abbreviations: ccRCC, clear-cell renal cell carcinoma; chRCC, chromophobe renal cell carcinoma; FNA, fine-needle aspirate; N/A, not applicable; NKP,
normal kidney parenchyma.
aDNA methylation profiling of normal adjacent tissue (NKP) included as part of this study.
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The methylation profiles of oncocytomas were most similar
to chRCC, consistent with the difficulty of distinguishing
oncocytoma from chRCC at the histological level. Despite
this, we observed a lower classification confidence for
oncocytoma compared with other sample types that were
represented in the study, indicated by lower posterior prob-
abilities for classification (Data Supplement). The uncertainty
of classifications for oncocytomas indicates that their meth-
ylation profiles do not perfectly match that of chRCC.
Comparative Surveys of Abnormal DNA Methylation in
Oncocytoma and chRCC Versus Normal Tissue
To characterize and compare the landscapes of abnormal
DNA methylation in oncocytoma and chRCC, we identified
CpGs that were significantly differentially methylated in
each histology compared with NKP separately. Overall,
there were 70% more abnormally methylated CpGs in
oncocytoma relative to NKP (n = 8,550 hypomethylated
CpGs; n = 962 hypermethylated CpGs) than in chRCC
relative to NKP (n = 5,058 hypomethylated CpGs; n = 517
hypermethylated CpGs) (Data Supplement). This is despite
considerable overlap between the sets of CpGs that were
abnormally methylated in each histology compared with
NKP: Two-thirds of the CpGs that were hypomethylated in
chRCC relative to NKP were also hypomethylated in onco-
cytoma (n = 3,377 of 5,058) and 58%of CpGs sites that were
hypermethylated in chRCC were hypermethylated in onco-
cytoma (n = 297 of 515), relative to NKP (Fig 2B). Onco-
cytomas also featured more extreme abnormal methylation
than chRCC in terms of themost extrememethylation β-value
differences between tumor and normal tissue (Fig 2A).
Differential Methylation Between Oncocytoma
and chRCC
To identify biomarkers that could distinguish oncocytoma
from chRCC, we next profiled differential methylation be-
tween these two histologies. We performed SAM analysis12
to identify CpGs that were most differentially methylated
between oncocytoma and chRCC samples. SAM analysis
identified 37 CpGs that were hypermethylated and 42 that
were hypomethylated in oncocytoma relative to chRCC,
with absolute mean β-value differences of up to 0.48 be-
tween oncocytoma and chRCC (Fig 3; Data Supplement).



























FIG 1. Multidimensional scaling analysis of differential DNA methylation between renal cell carcinoma (RCC)
subtypes and oncocytoma. Multidimensional scaling plot illustrating dissimilarity between RCC subtypes
(pRCC, ccRCC, and chRCC), NKP, and oncocytoma in terms of their DNA methylation profiles. The cytosine-
phosphate-guanine sites used for multidimensional scaling (n = 46,530) include all those that were used by
a diagnostic model that was trained on TCGA data to distinguish RCC subtypes. Unfilled circles represent TCGA
patient samples. Square points represent centroids for each of the TCGA sample groups (pRCC, ccRCC,
chRCC, and NKP). Filled circles represent Stanford study patient samples. ccRCC, clear-cell renal cell
carcinoma; chRCC, chromophobe renal cell carcinoma; KICH, kidney chromophobe (TCGA study abbrevi-
ation); KIRC, kidney renal clear cell carcinoma (TCGA study abbreviation); KIRP, kidney renal papillary cell
carcinoma (TCGA study abbreviation); NKP, normal kidney parenchyma; pRCC, papillary renal cell carcinoma;
RN, renal neoplasm; TCGA, The Cancer Genome Atlas.
Brennan et al
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reside within genes that were reported to be transcrip-
tionally deregulated in oncocytoma, including KRT7,
TSPAN5, NXPH2, ADCY5, IGFBP1.8
Development of a DNA Methylation-Based Diagnostic
Model to Distinguish Oncocytoma From chRCC
We trained a diagnostic model to distinguish chRCC by
using DNA methylation data for 79 CpGs that were dif-
ferentially methylated between the two histologies. We
tested the accuracy of this model in classifying oncocytoma
from chRCC on the basis of 10-fold cross-validation within
the Stanford study. This diagnostic model could distinguish
oncocytoma from chRCC with very high accuracy (area
under the receiver operating curve [AUC], 0.96; Fig 3B;
Data Supplement). Visualization of the methylation profile
of the only misclassified sample (oncocytoma_21) in-
dicates that this oncocytoma clearly displayed an NKP-like
methylation profile (Data Supplement).
DNAMethylation-Based Diagnostic Models to Distinguish
Oncocytoma From NKP and chRCC From NKP
We next tested the ability of methylation-based diagnostic
models to distinguish each renal mass histology (oncocy-
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FIG 2. Relative degrees of abnormal DNA methylation in oncocytoma and chRCC. (A) For (i) chRCC (n = 8) and (ii) oncocytoma (n = 15),
volcano plots illustrate the statistical significance (y-axes), and mean β value differences (x-axes) for differential methylation between tumor and
NKP (n = 12), of all cytosine-phosphate-guanine sites (CpGs). Red points represent CpGs with statistically significant methylation differences
(false-discovery-rate–corrected Wilcoxon rank-sum test, P , .05); green points indicate statistically significant CpGs with absolute β value
differences of. 0.2. (B) Scatter plot indicates change in β values (mean methylation β value in tumor minus mean methylation β value in NKP)
in oncocytoma and chRCC for CpGs that are shared between tumor types (abnormally methylated in both tumor types, in the same direction).
This indicates the relative degrees of differential methylation between tumor and histologically normal tumor-adjacent tissue for each renal mass
type, when considering CpGs that are abnormally methylated in both renal mass types. Venn diagrams indicate the number of overlapping
hypomethylated and hypermethylated CpGs between tumor types (*** P , .0001, hypergeometric test). Δ, change in; chRCC, chromophobe
renal cell carcinoma; NKP, normal kidney parenchyma.
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CpGs that were differentially methylated between each
histology and NKP. A diagnostic model that was trained to
distinguish oncocytoma from NKP accurately classified 11
of 12 oncocytomas and 15 of 15 NKP samples in 10-fold
cross-validation (AUC, 0.96; 95% CI, 0.88 to 1.00; Data
Supplement). Oncocytoma_21, the oncocytoma that was
previously misclassified as chRCC by our diagnostic model
to distinguish oncocytoma from chRCC, was here mis-
classified as NKP. A diagnostic model that was trained to
distinguish chRCC from NKP accurately classified 8 of 10
chRCCs and 15 of 15 NKP samples in 10-fold cross-validation
(AUC, 0.88; 95% CI, 0.71 to 1.00; Data Supplement).
We further evaluated if misclassification of oncocytoma_21
and two chRCC cases, because NKP could be explained by
lower tumor purity (ie, low fractions of tumor cells relative to
NKP). To do this, we applied InfiniumPurify15 to calculate
tumor purity scores for each sample and confirmed that
that these scores represent a valid measure of the fraction
of tumor cells within both chRCC and oncocytoma samples
(Data Supplement). Indeed, the tumor purity scores in each
of the three misclassified samples were much lower than
those of tumors that were correctly classified, and were
similar to NKP, indicating that these samples contain rel-
atively low tumor cell fractions (Data Supplement).
Validation of the Diagnostic Model in Independent
Patient Cohorts
We next sought to validate our diagnostic model to dis-
tinguish oncocytoma from chRCC in an independent
cg02693744









































































































AUC, 0.96 (95% CI, 0.88 to 1.00)












































FIG 3. Differential methylation distinguishing oncocytoma from chRCC. (A) Box plots illustrate methylation of cytosine-phosphate-guanine sites (CpGs)
that were differentially methylated between oncocytoma and chRCC within Stanford study data. Included are the top 10 statistically significant CpGs with
the greatest mean methylation differences between oncocytoma and chRCC. Methylation of the same CpGs in TCGA data for tumors in all three RCC
subtypes (pRCC, ccRCC, and chRCC) and NKP are shown for reference. Points represent individual patient samples. (B) Differential classification of
chRCC versus oncocytoma based on differential methylation of 79 CpGs (including those illustrated in A): (i) Heatmap indicating the posterior
probabilities (classification probability) for classification of patient samples as either chRCC or oncocytoma by a diagnostic model (prediction of
microarrays analysis13) in combination with 10-fold cross-validation. The true histological class of each sample is indicated by the color key, and the
probabilities for belonging to each of the two tumor type classes (chRCC or oncocytoma) are indicated in columns by the heatmap color gradient. (ii)
Received operating indicating the overall classification of the diagnostic model. The AUC is indicated with 95% CIs. (*) Misclassified sample
(oncocytoma 21). AUC, area under the receiver operating curve; ccRCC, clear-cell renal cell carcinoma; chRCC, chromophobe renal cell carcinoma;
kidney chromophobe (TCGA study abbreviation); KIRC, kidney renal clear cell carcinoma (TCGA study abbreviation); KIRP, kidney renal papillary cell
carcinoma (TCGA study abbreviation); NKP, normal kidney parenchyma; pRCC, papillary renal cell carcinoma; TCGA, The Cancer Genome Atlas.
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patient cohort. To do this, we trained the model on the
completed set of chRCCs, oncocytomas, and NPK samples
from the Stanford study (“training set”), and then applied it
to classify oncocytoma and chRCC tumors from in-
dependent patient studies (ie, “test set”). To build this test
set, we combined 37 formalin-fixed, paraffin-embedded
oncocytomas from Chopra et al.16 with the 65 TCGA chRCC
tumors. Our 79 CpGs diagnostic model correctly classified
62 of 65 chRCCs (95%) and 32 of 37 oncocytomas (86%;
multiple-class AUC, 0.87; Fig 4; Data Supplement). The
tumor purity scores of the 5 misclassified oncocytomas
were slightly lower than that for the correctly classified
oncocytomas (Data Supplement), although the mean dif-
ference in tumor purity scores between misclassified and
correctly classified oncocytomas was not statistically
significant.
Visual inspection of the separation of Stanford and Chopra
et al study oncocytomas from all TCGA samples by the full
CpG signature indicated that this signature separates
oncocytoma not only from chRCC but from all tissue types
included in the analysis (Fig 5). Moreover, this signature
separated oncocytomas from both the eosinophilic and
classic subtypes of chRCC to a similar extent (Data Sup-
plement), despite themuch greater histological and genetic
similarity of eosinophilic chRCC to oncocytoma.17,19 This
suggests it is possible to detect oncocytoma against
a background of NKP and distinguish oncocytoma from all
RCC subtypes using a manageable number of CpGs.
Development of a Minimal CpG Diagnostic Model
We investigated the minimal number of CpGs needed to
establish a diagnostic model that could robustly distinguish
oncocytoma from chRCC. This analysis revealed a set of 30
CpGs that could distinguish oncocytoma from chRCC with
optimal accuracy (ie, with accuracy equivalent to a model
using all 79 differentially methylated CpGs) within both the
Stanford data set and validation Chopra data set (Data
Supplement). These 30 CpGs represent those with the
highest discriminatory value to distinguish between onco-
cytoma and chRCC, as indicated in the Data Supplement.
Investigation of Ability of a Diagnostic Model to
Distinguish Core Needle Biopsy Specimens From
Oncocytoma and chRCC
As a preliminary investigation of the utility of DNA meth-
ylation data to differentially diagnose oncocytoma from
chRCC within presurgical biopsy specimens, we tested the
ability of our 79 CpGs model to distinguish chRCC (n = 6),
oncocytoma (n = 26), and NKP (n = 101) samples that were
collected as ex vivo core needle biopsy specimens reported
by Chopra et al.16 Classification accuracy for core needle
biopsy specimens was considerably lower than those for
tumor samples that were collected (multiple-class AUC,
0.73; Data Supplement). Moreover, the accuracy when
considering only classifications for tumor biopsy specimens
(ie, oncocytoma and chRCC biopsy specimens, excluding
NKP biopsy specimens) was particularly low (multiple-class
AUC, 0.45). Twelve of 26 oncocytomas (46%) were mis-
classified as NKP and had methylation profiles that clus-
tered with NKP (Data Supplement). We examined if this
misclassification could, again, be due to low tumor purity.
Indeed, the mean tumor purity score for misclassified
oncocytoma tumors was lower than for correctly classified
oncocytoma biopsy specimens (Data Supplement).
Moreover, the mean purity score for misclassified onco-
cytoma biopsy specimens was similar to NKP biopsy
specimens, whereas correctly classified oncocytoma bi-
opsy specimens had purity scores similar to resected
oncocytomas, suggesting the misclassified biopsy speci-
mens contain very low fractions of tumor cells.
We investigated if a tumor purity score could be used as
a quality-control measure to exclude biopsy specimens that
were below a certain threshold of purity. Indeed, 12 of 13
oncocytoma biopsy specimens with above-median purity
were correctly classified as oncocytoma by the diagnostic
methylation signature (92% accuracy), compared with only
2 of 13 oncocytoma biopsy specimens with below median
purity (15% accuracy).
Of the three patients with chRCC with available duplicate
biopsy specimens, one patient had both biopsy specimens
misclassified as oncocytoma. Because both biopsy spec-
imens were of high purity, this indicates the potential for
generation of false-positive results and overdiagnosis when
samples are collected by core needle biopsy.
DISCUSSION
We classified the DNA methylome of oncocytoma in terms
of its similarity to NKP and three RCC subtypes. This
revealed that oncocytomas are more similar to chRCC than
other RCC subtypes at the level of DNA methylation. And
the finding confirms the molecular similarity of oncocytoma
to chRCC, which was suggested by a previous study8 that
reported similar co-clustering of oncocytoma and chRCC
on the basis of gene expression.
A surprising finding of our study was that oncocytoma
features more extensive abnormal DNA methylation than
does chRCC. This contrasts with the genetic profiles of
oncocytoma and chRCC, because chRCC features several
concurrent nuclear genome alterations, whereas oncocy-
tomas have few nuclear genome alterations.20 The authors
of a recent study8 classified oncocytoma into two subtypes
on the basis of their genetic profiles, including a relatively
benign subtype, and a subtype with more mutations that
they speculated could progress to chRCC. Our observation
of greater epigenetic deregulation in oncocytoma than chRCC
conflicts with the hypothesis that oncocytoma represents
a precursor to chRCC.8 In addition to the previously reported
observations that oncocytomas possess genetic alterations
that are rare in chRCC,8.21 our observation of epigenetic
deregulation in oncocytoma that is absent in chRCC sug-
gests oncocytoma represents a distinct entity.
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FIG 4. Classification of tumors and core needle biopsy specimens from an independent patient study by a diagnostic model. Heatmaps illustrating posterior
probability (classification probability) for classification of (A) tumors and (B) core needle biopsy specimens from independent patient studies by
a methylation-based diagnostic model that was trained to distinguish oncocytoma from chRCC. (A) These validation-set tumors included chRCC tumors from
The Cancer Genome Atlas study (n = 65) and oncocytomas from a previous study reported by Chopra et al16 (n = 37). The (continued on following page)
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Although oncocytoma is considered benign,22 rare cases of
metastatic oncocytoma have been reported.23 Noting the
challenges in diagnosing oncocytoma, there is debate as
to whether these seemingly malignant oncocytoma cases
should be classified as oncocytoma, because they could
represent eosinophilic chRCCs or ccRCCs that have been
misdiagnosed as oncocytoma because of similar histological
profiles. On the basis of these observations, we suggest that
our DNA methylation signature be applied to future cases
of malignant tumors that are diagnosed histologically as
FIG 4. (Continued). model was trained using DNA methylation data for Stanford study chRCC, oncocytoma, and NKP samples (training set) to distinguish
among these three sample types, and its classification accuracy was then tested using validation-set DNA methylation data. The true histological class of
each sample is indicated by the color key, and the probabilities for belonging to each of the three classes (chRCC, oncocytoma, and NKP) are indicated in
columns by the heatmap color gradient. (B) Classification of ex vivo core needle biopsy specimens collected from chRCC (n = 6) and oncocytoma tumors (n =
26), as well as NKP tissue samples (n = 101) collected from patients with chRCC, oncocytoma, or other renal mass types (eg, papillary renal cell carcinoma,
























Chopra et al study16 needle biopsy specimen
Chopra et al study16 FFPE tumor
FIG 5. Multidimensional scaling plot illustrating similarity of tumors from the Chopra et al study16 to Stanford and
TCGA samples based on the diagnostic methylation signature. Multidimensional scaling (MDS) plots illustrating
patient samples from three studies in terms of their DNA profiles. Classic MDS was applied to methylation data for
61 cytosine-phosphate-guanine sites (CpGs) that were included within the 79 CpGs model that could distinguish
oncocytoma from chRCC (as illustrated in Fig 3B). These 61 CpGs represent those for which data were available for
all three studies. Open circles represent TCGA patient samples. Filled squares represent centroids for each of the
TCGA sample groups. Closed circles represent Stanford study patient samples. MDS illustrates the similarity of
Chopra et al16 study tumors to each of the sample classes. Text labels indicate samples that were misclassified by
our methylationmodels. ccRCC, clear-cell renal cell carcinoma; chRCC, chromophobe renal cell carcinoma; FFPE,
formalin-fixed, paraffin-embedded; KICH, kidney chromophobe (TCGA study abbreviation); KIRC, kidney renal clear
cell carcinoma (TCGA study abbreviation); KIRP, kidney renal papillary cell carcinoma (TCGA study abbreviation);
NKP, normal kidney parenchyma; pRCC, papillary renal cell carcinoma; TCGA, The Cancer Genome Atlas.
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oncocytoma, to determine if these cases truly represent
oncocytomas. This signature could help determine if
oncocytoma is universally benign, which would indicate
a need for deintensification of oncocytoma treatment.
Despite the overall molecular similarity of chRCC to
oncocytoma, we identified a methylation signature that can
robustly distinguish oncocytoma from chRCC in clinical
tumor samples using as few as 30 CpGs. This signature
includes hypermethylated genes in oncocytoma that were
previously reported as expression markers of oncocytoma,
suggesting that differential methylation represents the
underlying cause of this differential expression. Notably, we
observed hypermethylation of two CpGs within the pro-
moter of KRT7, lower expression of which distinguishes
oncocytoma from chRCC.24,25
Despite our focus on distinguishing oncocytoma from
chRCC specifically, we observed that the signature also
separated oncocytoma from ccRCC and pRCC, as well as
NPK. This suggests that, using this signature alone, it could
be possible to detect and distinguish oncocytoma from any
RCC subtype against a background of NKP. This signature
could be developed as a diagnostic biomarker to distinguish
oncocytoma from chRCC using existing technologies.26 This
would prevent misdiagnosis that could result in undertreat-
ment of chRCC and overtreatment of oncocytoma.7 Moreover,
this signature could help automate the labor-intensive process
of pathological diagnosis, perhaps in combination with sig-
natures that classify other RCC subtypes.27
We tested the ability of our signature to classify oncocytoma
in ex vivo core needle biopsy specimens as a preliminary
investigation of whether it might be possible to diagnose
oncocytoma using percutaneous renal mass biopsy
specimens. Preoperative diagnosis of oncocytoma would
enable patients to forego unnecessary surgery or to mini-
mize the need for surveillance after a percutaneous abla-
tion. Initially, the diagnostic signature in biopsy specimens
did not appear to provide any diagnostic value, because 12
of 14 oncocytoma biopsy specimens were misclassified as
NKP. We found, however, that the lower accuracy in biopsy
samples could be explained by biopsy specimen impurity.
This suggests that it could be possible to diagnose onco-
cytoma by applying our diagnostic signature in combination
with measures to optimize biopsy specimen purity and by
excluding impure biopsy specimens as inadequate. When
applied to biopsy specimens with greater than median
tumor purity, our signature classified biopsy specimens
with 92% accuracy. Although the current threshold of
tumor purity needed to achieve accurate classification of
needle biopsy specimens by our diagnostic signature is
high, reducing the overtreatment of even half of oncocy-
tomas would avoid thousands of unnecessary surgeries.
Potential optimization approaches that might help to im-
prove the classification accuracy are outlined in the Data
Supplement.
A limitation of our study is the modest sample size, which
limits our ability to establish a reliable estimate of the diagnostic
accuracy of the signature. Follow-up research is needed to
validate this signature as a biomarker to diagnose oncocytoma
in patient populations and to confirm that the signature can
accurately classify pure needle biopsy specimens.
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